Could Vir Biotechnology Be a Millionaire Maker Stock?
Vir Biotechnology (NASDAQ: VIR) may be weeks away from commercializing its very first product. The clinical-stage biotech company and partner GlaxoSmithKline late last month requested Emergency Use Authorization (EUA) for their investigational COVID-19 treatment.
In more good news, GlaxoSmithKline recently expanded its collaboration with Vir to include the development of potential treatments for respiratory viruses including influenza. And earlier in the year, Vir teamed up with Gilead Sciences to test their investigational chronic hepatitis B (HBV) treatments as a combination therapy. Vir shares are up 71% year to date. But they're down about 44% from a high reached in January. Now, you may be wondering how far they can go from here -- and whether they can make you a millionaire. Let's find out...
Image source: Getty Images.
Source Fool.com